Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.57 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.56 |
| ▸ | ALPI | P09923 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | XIAP | P98170 | 1/20 | 0.56 |
| ▸ | TPH1 | P17752 | 3/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.50 |
| ▸ | DRD3 | P35462 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17814914 | 1.00 | SLC7A5 (0.57) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL23069024 | 0.85 | NOS3 (0.55) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL23069027 | 0.85 | NOS3 (0.55) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL22669502 | 0.84 | GRIK1 (0.46) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL15511517 | 0.82 | SLC7A5 (0.41) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL29373039 | 0.82 | SLC7A5 (0.41) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL15469201 | 0.82 | SLC7A5 (0.41) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL15469207 | 0.82 | HSD17B10 (0.47) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL20339315 | 0.82 | HSD17B10 (0.47) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL15469227 | 0.81 | HSD17B10 (0.42) | SLC7A5PTGS1ALPIPKMXIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1371 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4689127-A1 | RF1 KO E. COLI STRAINS | Sutro Biopharma, Inc. (US) | 2026-02-11 | — | — | EP | claimed |
| US-12540197-B2 | Anti-tissue factor antibodies and antibody conjugates, compositions comprising anti-tissue factor antibodies or antibody conjugates, and methods of making and using anti-tissue factor antibodies and antibody conjugates | SUTRO BIOPHARMA, INC. (US) | 2026-02-03 | — | — | US | claimed |
| US-12534465-B2 | 5H-pyrrolo[3,2-d]pyrimidine-2,4-diamino compounds and antibody conjugates thereof | SUTRO BIOPHARMA, INC. (US) | 2026-01-27 | — | — | US | claimed |
| US-20250346650-A1 | ANTIBODIES WITH ENGINEERED CH2 DOMAINS, COMPOSITIONS THEREOF AND METHODS OF USING THE SAME | SUTRO BIOPHARMA INC (US) | 2025-11-13 | — | — | US | claimed |
| US-20250325633-A1 | CYTOKINE CONJUGATES FOR THE TREATMENT OF AUTOIMMUNE DISEASES | Synthorx, Inc. (US) | 2025-10-23 | — | — | US | claimed |
| US-20250325632-A1 | CYTOKINE CONJUGATES FOR THE TREATMENT OF PROLIFERATIVE AND INFECTIOUS DISEASES | Synthorx, Inc. (US) | 2025-10-23 | — | — | US | claimed |
| US-20250304723-A1 | MODIFIED FC PROTEINS COMPRISING SITE-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, CONJUGATES OF THE SAME, METHODS OF THEIR PREPARATION AND METHODS OF THEIR USE | SUTRO BIOPHARMA, INC. | 2025-10-02 | — | — | US | claimed |
| US-12427201-B2 | Anti-folate receptor antibody conjugates, compositions comprising anti-folate receptor antibody conjugates, and methods of making and using anti-folate receptor antibody conjugates | SUTRO BIOPHARMA, INC. (US) | 2025-09-30 | — | — | US | claimed |
| US-12421239-B2 | — | — | 2025-09-23 | — | — | US | claimed |
| US-12398197-B2 | Antibodies with engineered CH2 domains, compositions thereof and methods of using the same | SUTRO BIOPHARMA, INC. (US) | 2025-08-26 | — | — | US | claimed |
| WO-2018126229-A2 | POLYPEPTIDE-ANTIGEN CONJUGATES WITH NON-NATURAL AMINO ACIDS | SUTROVAX, INC. (US) | 2018-07-05 | — | — | WO | claimed |
| EP-3271359-A1 | ISOQUINOLIDINOBENZODIAZEPINES | Cellerant Therapeutics, Inc. (US) | 2018-01-24 | — | — | EP | claimed |
| US-9764039-B2 | Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use | SUTRO BIOPHARMA, INC. (US) | 2017-09-19 | — | — | US | claimed |
| US-9738724-B2 | Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use | SUTRO BIOPHARMA, INC. (US) | 2017-08-22 | — | — | US | claimed |
| US-9732161-B2 | Modified Fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use | SUTRO BIOPHARMA, INC. (US) | 2017-08-15 | — | — | US | claimed |
| WO-2017132617-A1 | ANTI-CD74 ANTIBODY CONJUGATES, COMPOSITIONS COMPRISING ANTI-CD74 ANTIBODY CONJUGATES AND METHODS OF USING ANTI-CD74 ANTIBODY CONJUGATES | SUTRO BIOPHARMA, INC. (US) | 2017-08-03 | — | — | WO | claimed |
| WO-2017132615-A1 | ANTI-CD74 ANTIBODY CONJUGATES, COMPOSITIONS COMPRISING ANTI-CD74 ANTIBODY CONJUGATES AND METHODS OF USING ANTI-CD74 ANTIBODY CONJUGATES | SUTRO BIOPHARMA, INC. (US) | 2017-08-03 | — | — | WO | claimed |
| WO-2016149546-A1 | ISOQUINOLIDINOBENZODIAZEPINES | CELLERANT THERAPEUTICS, INC. (US) | 2016-09-22 | — | — | WO | claimed |
| EP-3055321-A1 | NON-NATURAL AMINO ACID tRNA SYNTHETASES FOR PARA-METHYLAZIDO-L-PHENYLALANINE | Sutro Biopharma, Inc. (US) | 2016-08-17 | — | — | EP | claimed |
| WO-2015054587-A1 | NON-NATURAL AMINO ACID tRNA SYNTHETASES FOR PARA-METHYLAZIDO-L-PHENYLALANINE | SUTRO BIOPHARMA, INC. (US) | 2015-04-16 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250325633-A1 | CYTOKINE CONJUGATES FOR THE TREATMENT OF AUTOIMMUNE DISEASES | IL2, IL2RA, IL15 | SLC7A5 2484/4885PTGS1 1447/4885ALPI 1243/4885 |
| US-12427201-B2 | Anti-folate receptor antibody conjugates, compositions comprising anti-folate receptor antibody conjugates, and methods of making and using anti-folate receptor antibody conjugates | FOLR1, FOLR2, DHFR | SLC7A5 743/4885PTGS1 4083/4885ALPI 2698/4885 |
| US-20250304723-A1 | MODIFIED FC PROTEINS COMPRISING SITE-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, CONJUGATES OF THE SAME, METHODS OF THEIR PREPARATION AND METHODS OF THEIR USE | FCGR2A, FCGR3B, FCGR1A | SLC7A5 888/4885PTGS1 3984/4885ALPI 3252/4885 |
| US-12421239-B2 | — | FCGRT, DPYD, CD2BP2 | SLC7A5 2149/4885PTGS1 4683/4885ALPI 2040/4885 |
| US-20250325632-A1 | CYTOKINE CONJUGATES FOR THE TREATMENT OF PROLIFERATIVE AND INFECTIOUS DISEASES | IL2, IL2RA, IL36G | SLC7A5 1836/4885PTGS1 1611/4885ALPI 506/4885 |
| US-12534465-B2 | 5H-pyrrolo[3,2-d]pyrimidine-2,4-diamino compounds and antibody conjugates thereof | CD22, FCGR3B, FCGR2A | SLC7A5 689/4885PTGS1 2753/4885ALPI 2532/4885 |
| US-12540197-B2 | Anti-tissue factor antibodies and antibody conjugates, compositions comprising anti-tissue factor antibodies or antibody conjugates, and methods of making and using anti-tissue factor antibodies and antibody conjugates | VSIG8, F13B, HNRNPH3 | SLC7A5 1194/4885PTGS1 4003/4885ALPI 2042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.